小鼠中由推定缪氏肺孢子菌细胞表面肽酶诱导的B细胞与抗体应答可对抗实验性感染
研究将缪氏肺孢子菌推定表面蛋白SPD1在昆虫细胞表达并加MF-59佐剂皮下免疫小鼠,CD4清除后以2×10^5个肺孢子菌攻击,于攻击后4周和6周检测B细胞、记忆B细胞与特异性IgG。SPD1免疫组攻击前后特异性IgG升高、脾和肺B细胞与记忆B细胞绝对计数增加,攻击后6周缪氏肺孢子菌rRNA拷贝数显著低于未接受SPD1的小鼠。作者认为SPD1是预防或治疗肺孢子菌肺部感染的潜在疫苗候选。
要点
- 正常小鼠感染肺孢子菌后可产生针对SPD1的血清IgG应答,暴露于肺孢子菌的恒河猴血清也显示类似IgG应答。
- SPD1加MF-59佐剂皮下免疫使CD4清除Balb/c小鼠攻击后脾和肺B细胞及记忆B细胞绝对计数增加。
- SPD1免疫组攻击后6周缪氏肺孢子菌拷贝数显著低于未接受SPD1组,作者认为SPD1是潜在疫苗候选。
核心结论
- SPD1免疫对缪氏肺孢子菌感染提供保护效力,其保护与记忆B细胞产生增强和抗肺孢子菌IgG抗体产生增加相关。
- 作者认为SPD1是预防或治疗肺孢子菌肺部感染的潜在疫苗候选。
研究设计与样本
- 小鼠经皮下注射SPD1加MF-59佐剂免疫,末次免疫3周后用抗CD4抗体GK1.5清除CD4细胞,再以2×10^5个肺孢子菌攻击。
- 于攻击后4周和6周处死小鼠,采集脾/肺细胞和血清,用流式细胞术评估B细胞和记忆B细胞,用ELISA测特异性肺孢子菌IgG,用实时PCR测缪氏肺孢子菌rRNA。
- SPD1由单悬浮缪氏肺孢子菌囊胞经化学标记结合蛋白质组学鉴定,Broad Institute基因登录号PNEG_01848,并在昆虫细胞系表达。
主要发现
- 正常小鼠感染肺孢子菌后产生针对SPD1的血清IgG抗体应答,暴露于肺孢子菌的恒河猴血清对纯化SPD1显示类似血清IgG应答。
- SPD1免疫使CD4清除Balb/c小鼠攻击后脾和肺B细胞与记忆B细胞绝对细胞计数增加。
- SPD1免疫显著增加攻击前后特异性肺孢子菌IgG抗体产生。
- 攻击后6周,SPD1免疫小鼠的缪氏肺孢子菌拷贝数显著低于未接受SPD1的小鼠。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Pneumocystis pneumonia is a major cause of morbidity and mortality in HIV-infected subjects, cancer patients undergoing chemotherapy and solid organ transplant recipients. No vaccine is currently available. By chemical labeling coupled with proteomic approach, we have identified a putative surface protein (SPD1, Broad Institute gene accession number PNEG_01848) derived from single suspended P. murina cysts. SPD1 was expressed in an insect cell line and tested for vaccine development. METHODS: Mice were immunized with SPD1 plus adjuvant MF-59 by subcutaneous injection. Three weeks after the last immunization, CD4+ cells were depleted with anti-CD4 antibody GK1.5. The mice were then challenged with 2×105Pneumocystis organisms. Mice were sacrificed at 4 and 6weeks after PC challenge. Spleen/lung cells and serum were harvested. B cells and memory B cells were assessed via flow cytometry. Specific Pneumocystis IgG antibody was measured by ELISA before and after challenge. Infection burden was measured as real-time PCR for P. murina rRNA. RESULTS: Normal mice infected with Pneumocystis mounted a serum IgG antibody response to SPD1. Serum from rhesus macaques exposed to Pneumocystis showed a similar serum IgG response to purified SPD1. SPD1 immunization increased B cell and memory B cell absolute cell counts in CD4-depleted Balb/c mice post Pneumocystis challenge in spleen and lung. Immunization with SPD1 significantly increased specific Pneumocystis IgG antibody production before and after challenge. Mice immunized with SPD1 showed significantly decreased P. murina copy number compared with mice that did not receive SPD1 at 6weeks after challenge. CONCLUSION: Immunization with SPD1 provides protective efficacy against P. murina infection. SPD1 protection against Pneumocystis challenge is associated with enhanced memory B cell production and higher anti-Pneumocystis IgG antibody production. SPD1 is a potential vaccine candidate to prevent or treat pulmonary infection with Pneumocystis.
引用
- Ruan S, Cai Y, Ramsay AJ, et al. B cell and antibody responses in mice induced by a putative cell surface peptidase of Pneumocystis murina protect against experimental infection. Vaccine. 2016. PMID: 28012778. doi:10.1016/j.vaccine.2016.11.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。